NTLA: Intellia Therapeutics Inc Company Sales Revenue

Corporate emblem and logo of Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics (NTLA) leads the genome editing rights sector while avoiding price wars. The company's sold products demonstrate the dynamics of the business's fundamental share, where the 0.05 mark reflects the latest data. Revenues are based on future sales of CRISPR drugs for ATTR and edema. However, mutation risks and regulatory complexities create financial uncertainty for investors.

NTLA: Intellia Corp Revenue and Sales Volume 07/04/2022 - 11/17/2026

Analytical breakdowns for Intellia Therapeutics

Summary company analysis:NTLA, intelliatx.com
Original product of Intellia Therapeutics Inc

Intellia Therapeutics sales reflect daily cash inflows from product realization, allowing for the identification of hidden business degradation during periods of low market valuation. Growth in this metric confirms an expansion of operational scale, while a decline signals risks to margin positions. By analyzing the sales trajectory of Intellia Therapeutics, an investor assesses the effectiveness of technology commercialization. For Intellia Therapeutics (NTLA), this indicator characterizes the monetization of its developments. Outsourcing production and trials allows the company to focus on DNA innovations.

Analysis of competing companies

Tempus AI, Inc. (TEM) - Company Gross Revenue|Company Sales QGEN (Qiagen NV)|Revenue and Sales Volume Ionis Pharmaceuticals, Inc. (IONS)|Revenue and Sales Volume RGEN (Repligen Inc.)|Avidity Corp (RNA) - Company Total Revenue|CRSP - Company Revenue|Company Gross Revenue genedx.com WGS|Ultragenyx Pharmaceutical (RARE) - Company Revenue|Company Total Revenue Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Therapeutics) - Revenue and Sales Volume|Company Total Revenue Twist Bioscience Corp TWST|Revenue and Sales Volume TXG|Revenue and Sales Volume Stoke Therapeutics, Inc. (STOK)|Company Revenue BioLife BLFS|WVE - Company Sales|Maze Therapeutics Corp - Revenue and Sales Volume|Sionna Pharma - Company Total Sales|Prime Medicine (PRME) - Company Revenue|tayshagtx.com (TSHA) - Revenue and Sales Volume|Company Revenue uniQure Corp|MGTX: Company Sales Revenue|Revenue and Sales Volume RGNX|Company Gross Revenue Solid Corp|Revenue and Sales Volume OCGN (ocugen.com)|PACB (Pacific Biosciences) - Company Annual Revenue|Benitec Biopharma Inc - Revenue and Sales Volume|Company Gross Revenue Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Company Revenue|4D Molecular Therapeutics (FDMT) - Revenue and Sales Volume|LXEO (Lexeo Therapeutics, Inc.) - Revenue and Sales Volume|Company Total Revenue korrobio.com KRRO|Company Sales EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Company Sales Volume|Company Revenue ProQR Therapeutics N.V. PRQR|Company Gross Revenue Codexis, Inc. (CDXS)|SGMO - Company Revenue|nautilus.bio - Company Total Sales|Metagenomi, Inc (MGX) - Company Revenue|Company Sales Volume DTIL|Company Revenue Generation Bio|Revenue and Sales Volume Boundless Bio Inc|Company Revenue Exicure Corp (XCUR)|Company Gross Revenue Imunon|Revenue and Sales Volume PHIO (phiopharma.com)|Company Total Sales Volume mustangbio.com|RNAZ - Company Revenue|Company Total Revenue Bionano Genomics|APDN: Revenue and Sales Volume|Company Sales Volume BLUE|Company Sales IPA|OMGA: Company Sales Revenue|Revenue and Sales Volume OMIC|Company Gross Revenue Regulus Therapeutics|Company Revenue Syros SYRS|Company Sales Revenue TBIO|TCON: Company Sales|Unity Biotechnology, Inc. (UBX) - Company Sales